IL-17抑制剂与早期主要不良心血管事件
IMPORTANCE: The cardiovascular impact of biologics used in psoriasis is not fully understood. Several studies have suggested that the inhibition of the T-helper 17 cell pathway could lead to the destabilization of atherosclerotic plaques, leading to major adverse cardiovascular e…
要点
- 启动IL-17(R)A抑制剂后6个月内MACE风险与TNF-α抑制剂相比无显著差异。
- 不能完全排除轻度MACE风险增加,高危患者仍需关注。
核心结论
- 以TNF-α抑制剂为对照,启动IL-17(R)A抑制剂后6个月内未观察到MACE风险显著增加。
- 但不能完全排除轻度风险增加。
研究设计与样本
- 风险期为MACE前6个月,参考期为风险期前6个月;以接受TNF-α抑制剂(阿达木单抗或依那西普)治疗相似适应证者为活性对照。
- 数据分析于2023年4月至2024年8月进行。
主要发现
- 启动IL-17(R)A抑制剂与MACE无显著关联(OR 1.25,95%CI 0.75-2.08);TNF-α抑制剂启动与MACE的OR为0.90(95%CI 0.65-1.24)。
- 以TNF-α抑制剂为对照,启动IL-17(R)A抑制剂后6个月内MACE的OR为1.40(95%CI 0.77-2.54)。
- 首个敏感性分析拓宽MACE定义、第二个将风险期缩短至3个月,结果均未改变。
关键数值与推荐
- IL-17(R)A抑制剂与MACE:OR 1.25(95%CI 0.75-2.08)。
- TNF-α抑制剂与MACE:OR 0.90(95%CI 0.65-1.24)。
临床怎么用
- 银屑病等适应证患者启动IL-17(R)A抑制剂时,资料未显示6个月内MACE风险显著高于TNF-α抑制剂。
- 对心血管高危患者仍应保持关注,因不能完全排除轻度风险增加。
局限性
- 原文未报告具体局限性内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The cardiovascular impact of biologics used in psoriasis is not fully understood. Several studies have suggested that the inhibition of the T-helper 17 cell pathway could lead to the destabilization of atherosclerotic plaques, leading to major adverse cardiovascular events (MACEs). OBJECTIVE: To assess whether the initiation of interleukin (IL)-17(R)A inhibitors triggers MACEs. DESIGN, SETTING, AND PARTICIPANTS: In this case-time-control study using the French National Health Insurance database, all individuals who received IL-17(R)A inhibitors (secukinumab, ixekizumab, and brodalumab) from 2016 to 2021, were included and classified according to their cardiovascular risk level. The risk period was defined as the 6 months before the MACE, and the reference period as the 6 months before the risk period. The same design for patients who received tumor necrosis factor (TNF)-α inhibitors (adalimumab or etanercept) for similar indications (psoriasis, psoriatic arthritis, ankylosing spondylitis, or juvenile arthritis), as an active comparator. The data analysis was conducted between April 2023 and August 2024. EXPOSURE: The initiation of the biologic was screened in both periods. MAIN OUTCOMES AND MEASURES: The odds ratios (ORs) for the risk of MACEs were assessed following the initiation of IL-17(R)A inhibitors and TNF-α inhibitors independently. Subsequently, the OR for the risk of MACE associated with IL-17(R)A inhibitors was estimated using TNF-α inhibitors as the comparator. RESULTS: Among the 34 241 individuals who received an IL-17(R)A inhibitor, 381 MACEs were analyzed, including 176 acute coronary syndromes and 84 ischemic strokes in the main analysis. Initiation of IL-17(R)A inhibitors was not significantly associated with MACEs (OR, 1.25 [95% CI, 0.75-2.08] vs TNF-α inhibitor initiation and MACEs: OR, 0.90 [95% CI, 0.65-1.24]). Overall, the initiation of an IL-17(R)A inhibitor was not significantly associated with MACEs in the following 6 months, using TNF-α inhibitor as a comparator (OR, 1.40 [95% CI, 0.77-2.54]), regardless of the individual cardiovascular risk (P for homogeneity = .29). The definition of MACE was broadened in a first sensitivity analysis, and the risk period was shortened to 3 months in a second sensitivity analysis. The results did not change. CONCLUSIONS: In this case-time-control study based on a national insurance database, there was no evidence of a significant association between MACEs and the initiation of IL-17(R)A inhibitors, regardless of the individual cardiovascular risk of the patient. However, a modest risk increase cannot be entirely excluded.
引用
- Raby M, Balusson F, Oger E, et al. Interleukin-17 Inhibitors and Early Major Adverse Cardiovascular Events. JAMA Dermatol. 2025. PMID: 40900466. doi:10.1001/jamadermatol.2025.2972
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。